Property | Value |
?:abstract
|
-
Due to the COVID-19 pandemic, the Food and Drug Administration issued an Emergency Use Authorization to permit developers of certain serological tests to market their product prior to a comprehensive review. Nonetheless, the reliability of these assays is of great importance in order to be useful as a tool in estimating the relative proportions of different populations that have been exposed to SARS-CoV-2. We provide a sampling of 145 individuals from an ambulatory setting simultaneously tested with a qualitative point of care rapid finger prick Lateral Wave® IgM and IgG assay and a sample for the Mayo Clinic enzyme linked immunosorbent assay (ELISA) IgM/IgG antibody assay. Significant discrepancies did exist between the purported antibody responses as demonstrated by each assay.
|
is
?:annotates
of
|
|
?:creator
|
|
?:externalLink
|
|
?:journal
|
-
Annals_of_clinical_and_laboratory_science
|
?:license
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:source
|
|
?:title
|
-
Communication: Correlation of Point of Care SARS-CoV-2 Serological Assay with Quantitative ELISA.
|
?:type
|
|
?:year
|
|